文献速递血脂与心血管预防高血压冠心病

预测风险与预期获益指导CKM综合征心血管病一级预防决策

Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
PubMed 文献 · J Am Coll Cardiol · 2026-06-09

该科学声明由AHA与ACC发布,阐述在心血管-肾脏-代谢综合征(CKM)一级预防中,使用PREVENT方程(PREVENT-CVD、PREVENT-ASCVD、PREVENT-HF)进行结局特异性风险分层,并结合治疗相对风险降低估算预期获益(绝对风险降低),以指导CKM疗法的启动与强化及共享决策。

要点

  • PREVENT方程用于CKM综合征分期、亚临床心血管病检测及治疗决策。
  • 整合预测风险与治疗相对风险降低,估算预期获益以指导药物启动。
  • 强调风险评估作为共享决策第一步,并关注风险沟通与实施差距。

核心结论

  • 使用结局特异性PREVENT方程预测风险并结合预期获益,可指导CKM综合征患者心血管病一级预防的共享决策。

研究设计与样本

  • 美国心脏协会与美国心脏病学会发布的科学声明。

主要发现

  • 2025年高血压指南和2026年血脂异常指南均推荐使用PREVENT方程指导降压和降脂治疗的启动与强化。
  • 2026年CKM综合征指南推荐使用PREVENT方程及结局特异性风险阈值进行分期、亚临床心血管病检测和治疗决策。
  • 该声明详述了使用结局特异性PREVENT方程的理由、所选风险阈值的证据基础及推荐的人群层面潜在影响。

关键数值与推荐

  • 使用PREVENT-CVD、PREVENT-ASCVD和PREVENT-HF方程预测风险,结合治疗相对风险降低估算绝对风险降低。

临床怎么用

  • 将风险评估作为共享决策第一步,用于CKM综合征患者或高危人群的预防治疗决策。
  • 关注意识、风险沟通和证据-based预防措施实施方面的差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current clinical practice guidelines for the primary prevention of cardiovascular disease recommend risk assessment to align the type and intensity of preventive efforts with an individual's risk. The 2025 American Heart Association/American College of Cardiology guideline for the prevention, detection, evaluation, and management of high blood pressure in adults and the 2026 American Heart Association/American College of Cardiology guideline on the management of dyslipidemia incorporate quantitative risk assessment, recommending the PREVENT (Predicting Risk of Cardiovascular Disease Events) equations to guide initiation and intensification of antihypertensive and lipid-lowering therapies, respectively. Given the growing awareness of the clustering of cardiovascular-kidney-metabolic risk factors along with the expanding armamentarium of cardioprotective therapies for obesity, diabetes, and chronic kidney disease, a harmonized approach that comprehensively assesses and addresses risk across these interconnected conditions is needed. The 2026 American Heart Association/American College of Cardiology guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome provides recommendations for the use of the PREVENT equations with outcome-specific risk thresholds for staging, detection of subclinical cardiovascular disease, and decision-making regarding initiation and intensification of cardiovascular-kidney-metabolic therapies. This approach integrates predicted risk (using PREVENT-CVD [cardiovascular disease], PREVENT-ASCVD [atherosclerotic cardiovascular disease], and PREVENT-HF [heart failure]) with the relative risk reduction expected from treatment for each outcome to estimate the expected benefit (ie, absolute risk reduction) from drug therapy. This scientific statement details the rationale for using outcome-specific PREVENT equations, the evidence base for selected risk thresholds, and the potential population-level impact of these recommendations. This scientific statement also offers practical guidance for applying risk assessment as the first step in shared decision-making and for addressing gaps in awareness, risk communication, and optimal implementation of evidence-based preventive therapies to improve outcomes in individuals with or at risk for cardiovascular-kidney-metabolic syndrome.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Khan SS, Ndumele CE, Bhave N, et al. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2026. PMID: 42263012. doi:10.1016/j.jacc.2026.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。